Allergan Reduced Profit Estimates Again
March 18, 2016
Allergan (AGN) is supposed to be merging with Pfizer, but in the meantime AGN’s profit estimates have declined two straight qtrs.
Research Reports
I’m Not Happy With Pfizer’s Deal to Buy Allergan
January 1, 2016
Allergan (AGN) is merging with Pfizer which might curtail AGN’s plans of $25 in profits by 2017.
Still On Track
September 3, 2015
Allergan (AGN) continues to put out impressive results, and has the ability to go to $500 by 2017.
From Three to Four to Five
June 23, 2015
Allergan (AGN) has merged with Actavis and now this $300 stock could be headed to $400 — or $500.
Does ACT + AGN = $500?
November 18, 2014
Actavis (ACT) is buying Allergan (AGN) and my numbers say ACT could go to $500.
Allergan Looks to Salix to Fight Off Valeant
August 19, 2014
Allergan (AGN) is fighting off Valeant (VRX). Now Salix could be the help AGN needs.
Good News is Baked In
March 11, 2014
Allergan (AGN) was undervalued when I bought it last June. Now the stock’s overvalued and I’ll sell it from the Growth Portfolio.
No New News
December 4, 2013
There’s no new news to report on Allergan’s (AGN) RESTASIS generic competition, so let’s focus on the numbers — and the upside.
Not Doing Anything
September 18, 2013
Shares of Allergan (AGN) aren’t doing much of anything. Still, there’s good potential in this conservative growth stock. You just might have to sit & wait.
Collect a Franchise
June 25, 2013
Allergan (AGN) is a 15% grower that has had a P/E of 25 this decade. Today I will buy it for 18 times earnings for the Growth Portfolio.